HER2阳性乳腺癌新辅助治疗前乳腺MRI上瘤周与瘤内高T2信号强度:与组织病理学特征的关联评估
该回顾性研究纳入210例患者共211个HER2阳性乳腺癌,在新辅助治疗前乳腺MRI脂肪抑制T2加权成像上评估瘤周与瘤内高T2信号强度及其模式,分析其与组织病理学特征的关联。仅组织学分级3级与瘤周高T2信号强度独立相关(OR=1.90,p=.04),其余特征均无独立关联;瘤周与瘤内高T2信号强度对HER2阳性乳腺癌的预后标记效用总体有限。
要点
- HER2阳性乳腺癌中瘤周高T2信号强度占38.4%(81/211),瘤内高T2信号强度占45.0%(95/211)。
- 仅组织学分级3级与瘤周高T2信号强度独立相关(OR=1.90,p=.04)。
- 瘤周高T2信号强度预测各组织病理学特征的敏感度35.6%–43.7%、特异度59.7%–70.7%。
核心结论
- HER2阳性乳腺癌组织病理学特征与高T2信号强度之间唯一的独立关联为组织学分级3级与瘤周高T2信号强度;与既往在更广泛乳腺癌亚型中的报道不同,瘤周与瘤内T2信号强度作为HER2阳性乳腺癌预后标记的效用总体有限。
研究设计与样本
- 回顾性研究,纳入2015年1月1日至2022年7月30日期间接受新辅助治疗前乳腺MRI的210例患者(年龄24–82岁)共211个HER2阳性乳腺癌。
关键影像表现/征象
- 由两名放射科医师独立在脂肪抑制T2加权成像上评估瘤周高T2信号强度与瘤内高T2信号强度,意见不一致由第三名放射科医师裁决。
- 瘤周高T2信号强度分为邻近肿瘤型与胸肌前延伸型两种模式。
- 瘤周高T2信号强度者81个(38.4%),瘤内高T2信号强度者95个(45.0%)。
- 邻近肿瘤型高T2信号强度29个与胸肌前延伸型52个在各组织病理学特征频率上无显著差异(p>.05)。
诊断标准与关键数值
- 瘤周高T2信号强度预测组织病理学特征的敏感度35.6%–43.7%、特异度59.7%–70.7%。
- 瘤内高T2信号强度预测组织病理学特征的敏感度37.3%–49.6%、特异度49.3%–62.7%。
- 瘤周高T2信号强度评估的读者间一致性Gwet一致性系数=0.93,瘤内高T2信号强度Gwet一致性系数=0.89,瘤周高T2信号强度模式Gwet一致性系数=0.95。
临床应用与阅片要点
- 在脂肪抑制T2加权成像上评估HER2阳性乳腺癌的瘤周与瘤内高T2信号强度,读者间一致性几乎完美。
- 组织学分级3级与瘤周高T2信号强度独立相关(OR=1.90,p=.04),其余所评估组织病理学特征与瘤周或瘤内高T2信号强度均无独立关联(p>.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Intratumoral necrosis and peritumoral edema are features of aggressive breast cancer that may present as high T2 signal intensity (T2 SI). Implications of high T2 SI in HER2-positive cancers are unclear. OBJECTIVE. The purpose of this study was to assess associations with histopathologic characteristics of high peritumoral T2 SI and intratumoral T2 SI of HER2-positive breast cancer on MRI performed before initiation of neoadjuvant therapy. METHODS. This retrospective study included 210 patients (age, 24-82 years) with 211 HER2 breast cancers who, from January 1, 2015, to July 30, 2022, underwent breast MRI before receiving neoadjuvant therapy. Two radiologists independently assessed cancers for high peritumoral T2 SI and high intratumoral T2 SI on fat-suppressed T2-weighted imaging and classified patterns of high peritumoral T2 SI (adjacent to tumor vs prepectoral extension). A third radiologist resolved discrepancies. Multivariable logistic regression analyses were performed to identify associations of high peritumoral and intratumoral T2 SI with histopathologic characteristics (associated ductal carcinoma in situ, hormone receptor status, histologic grade, lymphovascular invasion, and axillary lymph node metastasis). RESULTS. Of 211 HER2-positive cancers, 81 (38.4%) had high peritumoral T2 SI, and 95 (45.0%) had high intratumoral T2 SI. A histologic grade of 3 was independently associated with high peritumoral T2 SI (OR = 1.90; p = .04). Otherwise, none of the five assessed histopathologic characteristics were independently associated with high intratumoral T2 SI or high peritumoral T2 SI (p > .05). Cancers with high T2 SI adjacent to the tumor (n = 29) and cancers with high T2 SI with prepectoral extension (n = 52) showed no significant difference in frequency for any of the histopathologic characteristics (p > .05). Sensitivities and specificities for predicting the histopathologic characteristics ranged from 35.6% to 43.7% and from 59.7% to 70.7%, respectively, for high peritumoral T2 SI, and from 37.3% to 49.6% and from 49.3% to 62.7%, respectively, for high intratumoral T2 SI. Interreader agreement was almost perfect for high peritumoral T2 SI (Gwet agreement coefficient [AC] = 0.93), high intratumoral T2 SI (Gwet AC = 0.89), and a pattern of high peritumoral T2 SI (Gwet AC = 0.95). CONCLUSION. The only independent association between histopathologic characteristics and high T2 SI of HER2-positive breast cancer was observed between a histologic grade of 3 and high peritumoral T2 SI. CLINICAL IMPACT. In contrast with previously reported findings in broader breast cancer subtypes, peritumoral and intratumoral T2 SI had overall limited utility as prognostic markers of HER2-positive breast cancer.
引用
- Jirarayapong J, Portnow LH, Chikarmane SA, et al. High Peritumoral and Intratumoral T2 Signal Intensity in HER2-Positive Breast Cancers on Preneoadjuvant Breast MRI: Assessment of Associations With Histopathologic Characteristics. AJR Am J Roentgenol. 2023. PMID: 38117101. doi:10.2214/AJR.23.30280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。